Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130822 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL31181359 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7130825 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL726079 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4376477 | 0.97 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL4376473 | 0.97 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL6324036 | 0.95 | ADORA2A (0.90) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6324041 | 0.95 | ADORA2A (0.90) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6411758 | 0.95 | ADORA2A (0.90) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6913647 | 0.95 | ADORA2A (0.90) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| US-6900309-B1 | Purine derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | claimed |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | PFIZER INC. | 2004-09-02 | — | — | US | claimed |
| EP-1395287-A1 | AN ADENOSINE A2A RECEPTOR AGONIST AND AN ANTICHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2004-03-10 | — | — | EP | claimed |
| US-20030109485-A1 | Pharmaceutical combination | PFIZER INC. | 2003-06-12 | — | — | US | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| WO-2002096462-A1 | AN ADENOSINE A2A RECEPTOR AGONIST AND AN ANTICHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2002-12-05 | — | — | WO | claimed |
| EP-2608794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | Northeastern University (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027695-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | NORTHEASTERN UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050232871-A1 | Use of compounds in a dry powder inhaler | HUMPHREY MICHAEL J | 2005-10-20 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20050124574-A1 | Purine derivatives | PFIZER INC. | 2005-06-09 | — | — | US | disclosed |
| EP-1395287-A1 | AN ADENOSINE A2A RECEPTOR AGONIST AND AN ANTICHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030109485-A1 | Pharmaceutical combination | PFIZER INC. | 2003-06-12 | — | — | US | disclosed |
| US-20030064034-A1 | Use of compounds in a dry powder inhaler | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002096462-A1 | AN ADENOSINE A2A RECEPTOR AGONIST AND AN ANTICHOLINERGIC AGENT IN COMBINATION FOR TREATING OBSTRUCTIVE AIRWAYS DISEASES | PFIZER INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002067909-A1 | NEW METHOD OF BRONCHODILATORY THERAPY | GLAXO GROUP LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20040171576-A1 | Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20050124574-A1 | Purine derivatives | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20030109485-A1 | Pharmaceutical combination | ADRA2B, ADRB2, ADRA2A | ADORA2A 6/4885ADORA3 13/4885ADORA1 12/4885 |
| US-20030064034-A1 | Use of compounds in a dry powder inhaler | QDPR, HRH4, HRH2 | ADORA2A 356/4885ADORA3 67/4885ADORA1 123/4885 |
| US-20050232871-A1 | Use of compounds in a dry powder inhaler | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, QDPR, IL5 | ADORA2A 775/4885ADORA3 254/4885ADORA1 414/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.